Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of PB-201 added to metformin in adults with inadequately controlled type 2 diabetes
CTR20220785Phase 3Active
- Sponsor
- PegBio
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing PB-201 + metformin with Placebo + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 24. Started Jul 2022; status: active.
02
Drugs
nerigliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220785.